These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 8539481)

  • 1. [Usefulness of the determination of C reactive protein and other acute phase proteins in rheumatoid arthritis].
    Galeazzi M; Morozzi G; Veronesi M; Ronconi S; Magi B; Bini L; Marcolongo R
    Recenti Prog Med; 1995 Nov; 86(11):456-62. PubMed ID: 8539481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The validity of surrogate markers in rheumatic disease.
    Emery P; Luqmani R
    Br J Rheumatol; 1993 Jun; 32 Suppl 3():3-8. PubMed ID: 7685227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rheumatoid arthritis exhibits reduced acute phase and enhanced constitutive serum amyloid A protein in synovial fluid relative to serum. A comparison with C-reactive protein.
    Kumon Y; Loose LD; Birbara CA; Sipe JD
    J Rheumatol; 1997 Jan; 24(1):14-9. PubMed ID: 9002005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
    Keyszer G; Lambiri I; Nagel R; Keysser C; Keysser M; Gromnica-Ihle E; Franz J; Burmester GR; Jung K
    J Rheumatol; 1999 Feb; 26(2):251-8. PubMed ID: 9972954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity.
    Gabay C; Cakir N; Moral F; Roux-Lombard P; Meyer O; Dayer JM; Vischer T; Yazici H; Guerne PA
    J Rheumatol; 1997 Feb; 24(2):303-8. PubMed ID: 9034987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative usefulness of C-reactive protein and erythrocyte sedimentation rate in patients with rheumatoid arthritis.
    Wolfe F
    J Rheumatol; 1997 Aug; 24(8):1477-85. PubMed ID: 9263138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do changes in clinical improvement in rheumatoid arthritis patients treated with immunosuppressive drugs reflect the changes in acute phase proteins?
    Lacki JK; Samborski W; Mackiewicz S; Mackiewicz U
    Ups J Med Sci; 1995; 100(3):233-42. PubMed ID: 8808186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validity of acute phase proteins as markers of disease activity.
    Blackburn WD
    J Rheumatol Suppl; 1994 Oct; 42():9-13. PubMed ID: 7529838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absence of correlation between interleukin 6 and C-reactive protein blood levels in systemic lupus erythematosus compared with rheumatoid arthritis.
    Gabay C; Roux-Lombard P; de Moerloose P; Dayer JM; Vischer T; Guerne PA
    J Rheumatol; 1993 May; 20(5):815-21. PubMed ID: 8336307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased levels of C-reactive protein in serum from blood donors before the onset of rheumatoid arthritis.
    Nielen MM; van Schaardenburg D; Reesink HW; Twisk JW; van de Stadt RJ; van der Horst-Bruinsma IE; de Gast T; Habibuw MR; Vandenbroucke JP; Dijkmans BA
    Arthritis Rheum; 2004 Aug; 50(8):2423-7. PubMed ID: 15334453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matrix metalloproteinases MMP-3 and MMP-1 levels in sera and synovial fluids in patients with rheumatoid arthritis and osteoarthritis.
    Mahmoud RK; El-Ansary AK; El-Eishi HH; Kamal HM; El-Saeed NH
    Ital J Biochem; 2005; 54(3-4):248-57. PubMed ID: 16688934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased serum levels of immunoglobulins, C-reactive protein, type 1 and type 2 cytokines in patients with mixed connective tissue disease.
    Bakri Hassan A; Rönnelid J; Gunnarsson I; Karlsson G; Berg L; Lundberg I
    J Autoimmun; 1998 Oct; 11(5):503-8. PubMed ID: 9802936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin 10 inhibits interleukin 6 production and acute phase response in rheumatoid arthritis.
    Lacki JK; Klama K; Porawska W; Mackiewicz SH; Müller W; Wiktorowicz K
    Arch Immunol Ther Exp (Warsz); 1995; 43(1):11-4. PubMed ID: 8744678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor.
    Rioja I; Hughes FJ; Sharp CH; Warnock LC; Montgomery DS; Akil M; Wilson AG; Binks MH; Dickson MC
    Arthritis Rheum; 2008 Aug; 58(8):2257-67. PubMed ID: 18668547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum amyloid A in the assessment of early inflammatory arthritis.
    Cunnane G; Grehan S; Geoghegan S; McCormack C; Shields D; Whitehead AS; Bresnihan B; Fitzgerald O
    J Rheumatol; 2000 Jan; 27(1):58-63. PubMed ID: 10648018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumour necrosis factor-alpha, interleukin-2 soluble receptor and different inflammatory parameters in patients with rheumatoid arthritis.
    Fröde TS; Tenconi P; Debiasi MR; Medeiros YS
    Mediators Inflamm; 2002 Dec; 11(6):345-9. PubMed ID: 12581498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IgG antibodies to type II collagen reflect inflammatory activity in patients with rheumatoid arthritis.
    Kim WU; Yoo WH; Park W; Kang YM; Kim SI; Park JH; Lee SS; Joo YS; Min JK; Hong YS; Lee SH; Park SH; Cho CS; Kim HY
    J Rheumatol; 2000 Mar; 27(3):575-81. PubMed ID: 10743792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis.
    Niederau C; Backmerhoff F; Schumacher B; Niederau C
    Hepatogastroenterology; 1997; 44(13):90-107. PubMed ID: 9058126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurement of serum hyaluronic acid in patients with rheumatoid arthritis: correlation with disease activity.
    Emlen W; Niebur J; Flanders G; Rutledge J
    J Rheumatol; 1996 Jun; 23(6):974-8. PubMed ID: 8782125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of rheumatoid arthritis--a clinician's viewpoint.
    Emery P
    J Rheumatol Suppl; 1994 Oct; 42():20-4. PubMed ID: 7823315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.